VX-770

VX-770 Basic information
Product Name:VX-770
Synonyms:Ivacaftor;Ivacaftor, >=98%;3-QuinolinecarboxaMide, N-[2,4-bis(1,1-diMethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-;N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide Ivacaftor (VX-770);N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide;N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxaMide;Ivacaftor (VX-770);VX 770, Ivacaftor
CAS:873054-44-5
MF:C24H28N2O3
MW:392.49
EINECS:
Product Categories:API;Inhibitors
Mol File:873054-44-5.mol
VX-770 Structure
VX-770 Chemical Properties
Melting point 212-215°C
Boiling point 550.4±50.0 °C(Predicted)
density 1.187
storage temp. Refrigerator
solubility DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
pka11.08±0.23(Predicted)
form Solid
color White to Light Brown
Safety Information
HS Code 29333990
MSDS Information
VX-770 Usage And Synthesis
DescriptionIn January 2012, the US FDA approved ivacaftor for the treatment of cystic fibrosis (CF) in patients who have the G551D mutation of the CF transmembrane regulator (CFTR) and are at least 6 years old. Ivacaftor (also known as VX-770) is a CFTR potentiator that increases the open probability of CFTR, thus increasing chloride secretion particularly in the 5% of CF patients with the G551D/F508 gating/ processing mutation. Ivacaftor was discovered by medicinal chemistry optimization of a lead scaffold identified through high-throughput screening of a 228,000 compound collection. In cultured bronchial epithelial cells from a CF patient with F508del, ivacaftor increased chloride secretion (EC50=81 nM). Preparation of ivacaftor is accomplished via a multistep synthesis oftwointermediates, 4-oxo-1,4-dihydroquinoline-3-carboxylic acid and 5-amino-di-tert-butylphenyl methyl carbonate, which are coupled using propane phosphonic acid anhydride (T3P) to afford the amide; deprotection of the phenol then provides ivacaftor.
OriginatorVertex Pharmaceuticals (United States)
UsesIvacaftor (VX-770, Kalydeco) is a potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively
UsesIvacaftor is used in the treatment of cystic fibrosis.
DefinitionChEBI: An aromatic amide obtained by formal condensation of the carboxy group of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid with the amino group of 5-amino-2,4-di-tert-butylphenol. Used for the treatment of cystic fibrosis.
Brand nameKalydeco
Clinical UseVertex’s ivacaftor was granted breakthrough therapy designation by the FDA in January 2012 for cystic fibrosis (CF) patients who bear the G551D mutation in the Cycstic Fibrosis Transmembrane Regulator (CFTR) gene. This CFTR mutation occurs in roughly 4% of the 30,000 people living with CF in the United States. While the compound has been identified as a potentiator in cell-based assays, its mechanism of action is as yet unknown.
SynthesisSeveral patents describe a synthesis of ivacaftor, only one demonstrates the synthesis on scale and includes yields, which is depicted in the scheme. Beginning with treatment of commercial di-tert-butylphenol derivative 91 with ethyl chloroformate, the synthesis of carbonate 92 was achieved in quantitative yield. Nitration of 92 provided the desired nitroarene regioisomer 93 in 57% yield which was isolated by recrystallization. Reduction of the newlyinstalled nitro group and subsequent amide bond formation via reaction with commercially available acid chloride 94 produced amide 95 in 53% yield over the two step sequence. Finally, cleavage of the carbonate unmasked the phenol to furnish ivacaftor (XV) in 96% yield.

Synthesis_873054-44-5

targetG551D-CFTR
references1. van goor f1, hadida s, grootenhuis pd, burton b, cao d, neuberger t, turnbull a, singh a, joubran j, hazlewood a, zhou j, mccartney j,arumugam v, decker c, yang j, young c, olson er, wine jj, frizzell ra, ashlock m, negulescu p. rescue of cf airway epithelial cell function in vitro by a cftr potentiator, vx-770. proc natl acad sci u s a. 2009 nov 3;106(44):18825-30. 2. vachel l1, norez c, becq f, vandebrouck c. effect of vx-770 (ivacaftor) and oag on ca2+ influx and cftr activity in g551d and f508del-cftr expressing cells. j cyst fibros. 2013 dec;12(6):584-91
VX-770 Preparation Products And Raw materials
Ataluren (PTC124) PLX4032 Rapamycin Pimodivir CFTRinh-172 Atazanavir Voriconazole 6-Mercaptopurine VX-661 Liraglutide VX-809 Telaprevir VE 822 Citalopram AVN-944 Iodixanol (S)-1-((S)-2-(4-amino-3-chlorobenzamido)-3,3-dimethylbutanoyl)-N-((2R,3S)-2-ethoxy-5-oxotetrahydrofuran-3-yl)pyrrolidine-2-carboxamide Bumetanide

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.